PHASE II TRIAL OF BEVACIZUMAB AND ERLOTINIB IN ADVANCED BILIARY TUMORS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 (from ClinicalTrials.gov网站） 单克隆抗体，如贝伐单抗，可以以不同的方式阻断肿瘤生长。一些阻断肿瘤细胞生长和扩散的能力。其他人则发现肿瘤细胞并帮助杀死它们或将杀死肿瘤的物质携带给它们。厄洛替尼可以通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。贝伐单抗和厄洛替尼也可以通过阻断流向肿瘤的血液来阻止肿瘤细胞的生长。贝伐单抗与厄洛替尼联合使用可能会杀死更多的肿瘤细胞。 这项II期试验正在研究贝伐单抗与厄洛替尼联合治疗转移性或不可切除的胆道肿瘤患者的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and erlotinib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with erlotinib may kill more tumor cells. This Phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with metastatic or unresectable biliary tumors.